Work

Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.9055

Authors: Charu Aggarwal, Mary Weber Redman, Primo Lara, Hossein Borghaei, Philip C. Hoffman, Jeffrey D. Bradley, Katie Griffin, Jieling Miao, Philip C. Mack, Vassiliki Papadimitrakopoulou, Roy S. Herbst, Karen Kelly, David R. Gandara

Institutions: Abramson Cancer Center, Fred Hutch Cancer Center, University of California, Davis, Fox Chase Cancer Center, University of Chicago Medical Center, Washington University in St. Louis, UC Davis Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Yale University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2763343361

Cites:

Cited by: 17

Related to: 10